Meeting NewsVideo

VIDEO: Complete depletion of peripheral B cells with obinutuzumab in lupus nephritis

WASHINGTON — At ASN Kidney Week, Brad H. Rovin, MD, presented results of the NOBILITY trial, a phase 2 randomized, controlled study of obinutuzumab with mycophenolate and corticosteroids in patients with proliferative lupus nephritis.

He said patients with proliferative lupus nephritis who received obinutuzumab showed a rapid and complete depletion of peripheral B cells without an increase in serious adverse events, serious infections and death compared to the standard of care through week 76 of the study. Patients also had significant improvement in serologies and proteinuria.

WASHINGTON — At ASN Kidney Week, Brad H. Rovin, MD, presented results of the NOBILITY trial, a phase 2 randomized, controlled study of obinutuzumab with mycophenolate and corticosteroids in patients with proliferative lupus nephritis.

He said patients with proliferative lupus nephritis who received obinutuzumab showed a rapid and complete depletion of peripheral B cells without an increase in serious adverse events, serious infections and death compared to the standard of care through week 76 of the study. Patients also had significant improvement in serologies and proteinuria.

    See more from American Society of Nephrology Annual Meeting